Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  PledPharma AB (publ)    PLED   SE0003815604

PLEDPHARMA AB (PUBL) (PLED)
Mes dernières consult.
Most popular
Report
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

PledPharma publ : The Aladote study in patients treated for paracetamol overdose is now open for recruitment for the next dosage group

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 01:46pm CET


The data safety monitoring committee gave the approval to initiate the next cohort in the open-label, randomised, rising dose design, proof-of-principle safety and tolerability study with Aladote in patients treated with NAC for paracetamol overdose.       

The study is conducted at the University of Edinburgh, Queen’s Medical Research Institute in Scotland and will involve a total of 24 patients assigned into one of 3 dosing cohorts of 8 patients.

The first cohort receiving the lowest dose of the study drug has been completed and after reviewing the safety data the monitoring committee, in a meeting held on September 13, approved to continue with recruitment for the middle dose group.

 

For more information, please contact:

Nicklas Westerholm, CEO, phone: +46 73 354 20 62
[email protected]

Michaela Gertz, CFO, phone: +46 709 26 17 75
[email protected]

About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company's most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A phase IIb study has been conducted and will serve as the basis for the continued development. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 80 00). For more information, see www.pledpharma.se

 

Copyright © 2017 OMX AB (publ), source OMX

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PLEDPHARMA AB (PUBL)
2017 PRINCIPAL INVESTIGATOR JAMES DEAR PR : PledPharma announces that an abstract pre..
2017 PLEDPHARMA PUBL : First patient included in Phase I study aiming at supporting e..
2017 PLEDPHARMA PUBL : First patient included in Phase I study aiming at supporting e..
2017 PLEDPHARMA PUBL : and Solasia enter license agreement to develop and commerciali..
2017 PLEDPHARMA PUBL : and Solasia enter license agreement to develop and commerciali..
2017 PledPharma and Solasia enter license agreement to develop and commercialize P..
2017 PLEDPHARMA PUBL : PledPharmas Phase IIb study with PledOx (PLIANT) published in ..
2017 PLEDPHARMA PUBL : Phase IIb study with PledOx® (PLIANT) published in Acta Oncolo..
2017 PLEDPHARMA PUBL : initiates Phase III studies with PledOx® before year end 2017
2017 PLEDPHARMA PUBL : appoints Yilmaz Mahshid as new CFO
More news
Financials ( SEK)
Sales 2017 8,00 M
EBIT 2017 -67,0 M
Net income 2017 -66,8 M
Finance 2017 326 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 75,4x
EV / Sales 2018 0
Capitalization 930 M
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Nicklas Westerholm Chief Executive Officer
Håkan Åström Chairman
Stefan Carlsson Chief Medical Officer & VP-Clinical Development
Magnus Andreas Bunge Director
Eva Margareta Redhe Director
Sector and Competitors
1st jan.Capitalization (M$)
PLEDPHARMA AB (PUBL)115
GILEAD SCIENCES14.10%105 754
VERTEX PHARMACEUTICALS4.76%39 951
REGENERON PHARMACEUTICALS-0.50%39 917
GENMAB10.50%11 762
EXELIXIS, INC.-9.57%8 284